Gujarat Themis Biosyn Limited has informed the Exchange about Commencement of commercial production/operations

Business Updates View source PDF Explain this filing

GUJTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.9%Reaction day

₹262.25

prior close

₹252.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%+3.6% vs market

Pharmaceuticals peers, median of 146sector+0.5%+4.4% vs sector

On the reaction day the stock moved 3.6 pts more than Nifty Microcap 250 and 4.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.7

10m

+2.7

15m

+3.0

30m

+2.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.9+1.3+3.6+0.5+4.4

Next day

+1.0+0.4+0.6-0.5+1.5

+2.6+0.3+2.3-0.8+3.4

+13.1+5.0+8.1+2.3+10.8

+16.3+6.7+9.6+2.9+13.4

+20.1+8.4+11.7+3.8+16.3

+27.7+10.3+17.4+4.8+22.9

15d

+15.5+12.8+2.7+7.3+8.3

+32.7+16.0+16.7+5.9+26.8

+31.6+16.9+14.7+8.3+23.3

+35.4+12.5+22.8+5.3+30.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 146Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gujarat Themis Biosyn has started commercial production at its newly set up API manufacturing plant located at 69/C GIDC Industrial Estate, Vapi, Gujarat, effective May 6, 2025. The facility is a multi-purpose plant designed for both synthetic and fermentation-based production of Active Pharmaceutical Ingredients (APIs) and Intermediates for the pharmaceutical industry. The company says the plant will support its forward integration plans and strengthen its presence in export markets, particularly the United States and Europe. No revenue figures, production capacity numbers, or specific order details were disclosed in the filing.

Likely market impact

This is an operational milestone that adds new manufacturing capacity and positions the company for growth in regulated overseas markets, which could be positive for long-term revenue. However, without disclosed volumes, capacity, or order book details, the immediate stock impact is likely to be limited.